Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

pharmaceutical solution industries (psi), saudi arabia - sodium chloride,sodium acetate,dextrose,potassium chloride, calcium chloride,magnesium chloride - solution - 199.22,174.34,17.325,6.78,6.43,5.34 g/l,

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

pharmaceutical solution industries (psi), saudi arabia - dextrose,sodium chloride,sodium gluconate,sodium acetate,potassium chloride,magnesium chloride - solution - 55,5.26,5.02,3.68,0.37,0.3 g,

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

pharmaceutical solution industries (psi), saudi arabia - dextrose,sodium chloride,sodium gluconate,sodium acetate,potassium chloride,magnesium chloride - solution - 55,5.26,5.02,3.68,0.37,0.3 g,

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

pharmaceutical solution industries (psi), saudi arabia - dextrose,sodium chloride,sodium gluconate,sodium acetate,potassium chloride,magnesium chloride - solution - 55,5.26,5.02,3.68,0.37,0.3 g,

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

pharmaceutical solution industries (psi), saudi arabia - dextrose,sodium chloride,sodium gluconate,sodium acetate,potassium chloride,magnesium chloride - solution - 55,5.26,5.02,3.68,0.37,0.3 g,

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - levetiracetam, quantity: 1000 mg - tablet, film coated - excipient ingredients: povidone; magnesium stearate; colloidal anhydrous silica; croscarmellose sodium; maize starch; titanium dioxide; hypromellose; macrogol 6000 - use in epileptic patients aged 4 years and older, initially as add on therapy, in the treatment of partial onset seizures with or without secondary generalisation,,monotherapy in the treatment of partial onset seizures, with or without secondary generalisation, in patients from 16 years of age with newly diagnosed epilepsy.,add on therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy (jme), and,add on therapy in the treatment of primary generalized tonic-clonic seizures in adults and children from 4 years of age with idiopathic generalized epilepsy (ige).

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - levetiracetam, quantity: 500 mg - tablet, film coated - excipient ingredients: maize starch; povidone; croscarmellose sodium; colloidal anhydrous silica; magnesium stearate; titanium dioxide; hypromellose; iron oxide yellow; macrogol 400 - use in epileptic patients aged 4 years and older, initially as add on therapy, in the treatment of partial onset seizures with or without secondary generalisation,,monotherapy in the treatment of partial onset seizures, with or without secondary generalisation, in patients from 16 years of age with newly diagnosed epilepsy.,add on therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy (jme), and,add on therapy in the treatment of primary generalized tonic-clonic seizures in adults and children from 4 years of age with idiopathic generalized epilepsy (ige).

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - levetiracetam, quantity: 250 mg - tablet, film coated - excipient ingredients: magnesium stearate; maize starch; colloidal anhydrous silica; povidone; croscarmellose sodium; titanium dioxide; hypromellose; macrogol 400; indigo carmine aluminium lake - use in epileptic patients aged 4 years and older, initially as add on therapy, in the treatment of partial onset seizures with or without secondary generalisation,,monotherapy in the treatment of partial onset seizures, with or without secondary generalisation, in patients from 16 years of age with newly diagnosed epilepsy.,add on therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy (jme), and,add on therapy in the treatment of primary generalized tonic-clonic seizures in adults and children from 4 years of age with idiopathic generalized epilepsy (ige).

New Zealand - English - Medsafe (Medicines Safety Authority)

aft pharmaceuticals ltd - desmopressin acetate trihydrate 0.6mg equivalent to desmopressin 0.089 mg/ml;   - nasal spray solution - 0.1 mg/ml - active: desmopressin acetate trihydrate 0.6mg equivalent to desmopressin 0.089 mg/ml   excipient: chlorobutanol hemihydrate hydrochloric acid nitrogen purified water sodium chloride

New Zealand - English - Medsafe (Medicines Safety Authority)

aft pharmaceuticals ltd - desmopressin acetate trihydrate 0.1mg equivalent to desmopressin 0.0890 mg;   - tablet - 100 mcg - active: desmopressin acetate trihydrate 0.1mg equivalent to desmopressin 0.0890 mg   excipient: lactose monohydrate magnesium stearate maize starch povidone